Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19GlobeNewsWire • 10/08/20
Is Emergent Biosolutions (EBS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/05/20
Emergent Biosolutions (EBS) Up 21.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 08/29/20
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of DirectorsGlobeNewsWire • 08/26/20
What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President TrumpThe Motley Fool • 08/25/20
Looking for a Growth Stock? 3 Reasons Why Emergent Biosolutions (EBS) is a Solid ChoiceZacks Investment Research • 08/24/20
UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 MonthsGlobeNewsWire • 08/17/20
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 MonthsGlobeNewsWire • 08/17/20
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028GlobeNewsWire • 08/07/20
Emergent Biosolutions (EBS) is an Incredible Growth Stock: 3 Reasons WhyZacks Investment Research • 08/06/20